MUCIN EXPRESSION IN CYSTIC FIBROSIS & NORMAL EPITHELIUM
Project Number7R29HL050694-02
Contact PI/Project LeaderVOYNOW, JUDITH A
Awardee OrganizationDUKE UNIVERSITY
Description
Abstract Text
DESCRIPTION: (Adapted from the applicant's abstract and Specific Aims.)
Cystic Fibrosis (CF) is the most common fatal inherited disease in
Caucasians. A characteristic pathologic feature is the blockage of
exocrine glands in mucus-rich respiratory, gastrointestinal and
reproductive tracts which is the basis for the generally held assumption
that CF mucus is abnormal. Although the CF gene and gene product, the
Cystic Fibrosis transmembrane conductance regulatory (CFTR) have been
identified, their relationship to the mucus abnormality is not defined.
Since mucin glycoproteins (mucins) are the major macromolecular
components of mucus and are responsible for its viscoelastic properties
in vivo, alterations in mucins may effect the physiologic behavior of
mucus. There are at least four human mucin protein genes expressed in
respiratory epithelium; the relative expression of these genes is not
known in CF or non-CF epithelium. This application proposes to determine
the relative expression of mucin genes in CF and normal epithelium. The
long term objective is to elucidate the role of airway mucins in health
and disease. The Specific Aims of the present application are: 1) to
measure levels of mucin mRNA transcripts in freshly obtained CF and
normal nasal epithelial cells and immortalized CF cell lines and matched
CF cell lines which have been transfected with the wild-type CFTR gene
using a newly developed quantitative mucin RNA method; 2) to test
inflammatory mediators known to affect secretion of high molecular weight
glycoproteins and known to be present in CF airways to identify agents
which modulate expression of specific mucin genes at the transcriptional
level in epithelial cells; and 3) to quantitate levels of secreted and
cellular mucin proteins in a cell line under resting or stimulated
conditions using enzyme linked immunosorbent assays (ELISAs) with
specific anti-mucin-peptide antibodies to elucidate whether mucin
production is regulated at the transcriptional, translational and/or
secretory levels. The information derived from the proposed experiments
may fill a major gap in understanding the mucus/mucin abnormality in CF
as well as provide basic information about mucin expression in
respiratory epithelium.
No Sub Projects information available for 7R29HL050694-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R29HL050694-02
Patents
No Patents information available for 7R29HL050694-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R29HL050694-02
Clinical Studies
No Clinical Studies information available for 7R29HL050694-02
News and More
Related News Releases
No news release information available for 7R29HL050694-02
History
No Historical information available for 7R29HL050694-02
Similar Projects
No Similar Projects information available for 7R29HL050694-02